Genovis AB (publ.) GENO
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
The founder owns or has owned shares in this company within the past 6 months. See About.
Existing position can be maintained pending clearer margin trends in upcoming reports.
Stable growth and a strong cash position are balanced by currency pressure and integration risks, supporting a neutral stance.
The market is neutral to slightly positive with focus on underlying growth despite currency headwinds and one-off costs.
HOLD is the call. Neutral is the market mood. Medium risk means some things can go wrong.
Latest change
- 11 Nov 2026 — The report shows strong growth driven by higher demand in the ADC segment and new product launches.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (5) — follow the company freeAbout the company
Genovis develops and sells SmartEnzymes and antibodies for protein analysis, diagnostics and development of biological drugs. The company is in a growth phase with focus on organic expansion and acquisitions such as KPL ApS. Operations feature high gross margins and positive cash flow.
Bull case
Strong adjusted EBITDA and new products provide momentum ahead of upcoming reports.
Bear case
Currency headwinds and one-off costs weigh on reported results.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| KPL ApS integration | Delayed integration → lower margin improvement than expected during 2026-2027. | Rapid integration → higher revenue growth and margin expansion from H2 2026. |
| New enzyme launches | Fewer launches than planned → weaker organic growth in the protein analysis segment. | Multiple successful launches → increased demand and broader customer base. |
| SEK/USD-EUR exchange rate | Stronger krona → continued pressure on reported revenue and earnings. | Weaker krona → higher reported growth and improved profitability. |
Why this signal
Stable growth and a strong cash position are balanced by currency pressure and integration risks, supporting a neutral stance.
Recent news
Genovis released the Q3 report on 10 November showing net sales of SEK 36.9m (+34 %) and EBITDA of SEK 10.3m (+50 %). The share rose sharply on the report.